The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020.
Third-quarter revenue slipped to 14.74 billion Swiss francs ($14.84 billion), below market expectations of about 15.5 billion francs.

The company reaffirmed its guidance for full-year revenue to be flat or grow by a "low-single digit" percentage, when excluding foreign exchange effects.

Demand in China was recovering as people started seeing their doctors again after harsh lockdown measures but was not yet back to pre-pandemic levels, Roche's CEO said.

Market expectations have picked up after rivals Eisai and Biogen (NASDAQ: ) last month reported positive results on a drug that targets the same protein type, but Schwan declined to comment on any implications for gantenerumab.
Source: Investing.com
#Roche